$16.26
4.63% yesterday
Nasdaq, Nov 15, 09:47 pm CET
ISIN
US0453961080
Symbol
ASMB
Sector
Industry

Assembly Biosciences, Inc. Stock price

$16.14
-2.38 12.85% 1M
+1.53 10.47% 6M
+6.30 64.00% YTD
+7.28 82.25% 1Y
-17.58 52.14% 3Y
-139.86 89.65% 5Y
-86.94 84.34% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.91 5.34%
ISIN
US0453961080
Symbol
ASMB
Sector
Industry

Key metrics

Market capitalization $102.59m
Enterprise Value $9.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.40
EV/Sales (TTM) EV/Sales 0.32
P/S ratio (TTM) P/S ratio 3.62
P/B ratio (TTM) P/B ratio 3.94
Revenue (TTM) Revenue $28.33m
EBIT (operating result TTM) EBIT $-46.44m
Free Cash Flow (TTM) Free Cash Flow $22.84m
Cash position $94.95m
EPS (TTM) EPS $-7.14
P/E forward negative
P/S forward 4.42
EV/Sales forward 0.61
Short interest 0.38%
Show more

Is Assembly Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Assembly Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Assembly Biosciences, Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Assembly Biosciences, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Assembly Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
28 28
-
100%
- Direct Costs 0.18 0.18
63% 63%
1%
28 28
5,845% 5,845%
99%
- Selling and Administrative Expenses 22 22
11% 11%
77%
- Research and Development Expense 53 53
4% 4%
186%
-46 -46
39% 39%
-163%
- Depreciation and Amortization 0.18 0.18
63% 63%
1%
EBIT (Operating Income) EBIT -46 -46
39% 39%
-164%
Net Profit -41 -41
44% 44%
-144%

In millions USD.

Don't miss a Thing! We will send you all news about Assembly Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Assembly Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
4 months ago
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
Neutral
GlobeNewsWire
5 months ago
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
Neutral
GlobeNewsWire
6 months ago
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inh...

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jason Okazaki
Employees 65
Founded 2005
Website www.assemblybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today